1. Which of the following correctly defines autonomic tone and explains why different organs exhibit different dominant autonomic tone at rest?

• A) Autonomic tone refers to the maximal possible activation of an effector organ by either sympathetic or parasympathetic stimulation -- organs with high tone are those capable of the greatest absolute response to pharmacological agonism; the heart has the highest autonomic tone because it can increase its rate from 60 to 200 bpm (a 233% increase), while the pupil has low tone because dilation is limited by iris anatomy; drugs that increase tone are called tonomimetics and those that reduce it are called tonoplegics.
• B) Autonomic tone refers to the level of ongoing background neural activity from the autonomic nervous system that maintains baseline effector organ function between discrete reflex responses -- tonic activity is not zero at rest; different organs exhibit different dominant tone because the CNS maintains different set points of sympathetic versus parasympathetic drive to each organ based on physiological priorities; the heart at rest is under dominant parasympathetic (vagal) tone -- intrinsic SA node automaticity would fire at 100-110 bpm without any autonomic input, but resting vagal M2 activation slows it to 60-70 bpm; atropine (blocking vagal tone) raises resting heart rate toward the intrinsic rate, confirming dominant vagal tone; the vasculature is under dominant sympathetic alpha-1 tone -- sympathectomy produces vasodilation and hypotension; the iris is under dominant parasympathetic tone for the sphincter (pupil constricts to midpoint at rest) -- atropine produces mydriasis; the bronchi are under dominant parasympathetic tone -- atropine produces bronchodilation; the GI tract is under dominant parasympathetic (ENS + vagal) tone for motility.
• C) Autonomic tone is a fixed property determined genetically -- individuals are born with either sympathetic-dominant or parasympathetic-dominant tone affecting all organs simultaneously; sympathetic-dominant individuals have resting heart rates above 90 bpm, dilated pupils, dry skin, and reduced bowel sounds; parasympathetic-dominant individuals have resting heart rates below 55 bpm, miotic pupils, moist skin, and hyperactive bowel sounds; beta-blockers are used to shift sympathetic-dominant individuals toward parasympathetic tone.
• D) Autonomic tone is synonymous with receptor density -- organs with high autonomic tone have high receptor density; organs with low tone have sparse receptor expression; the heart's high parasympathetic tone reflects the dense M2 receptor expression in SA and AV nodal tissue; the vasculature's high sympathetic tone reflects dense alpha-1 receptor expression in vascular smooth muscle; drugs that upregulate receptor density increase tone and drugs that downregulate receptor density reduce tone.
• E) Autonomic tone refers exclusively to sympathetic activity -- parasympathetic activity is episodic and reflex-driven, not tonic; the concept of resting parasympathetic tone is a historical misconception corrected by microneurography studies showing that vagal efferent firing is absent between heartbeats at rest; the heart rate at rest is therefore entirely set by intrinsic SA node automaticity without any tonic vagal influence; atropine raises heart rate not by blocking tonic vagal activity but by sensitizing SA node beta-1 receptors to circulating catecholamines.

2. The concept of sympathetic-parasympathetic antagonism is often overstated. Which of the following most accurately describes the relationship between the two autonomic divisions at effector organs, and identifies organs where both divisions produce the SAME effect?

• A) Sympathetic and parasympathetic divisions always produce strictly opposing effects at every effector organ -- where sympathetic stimulation increases an organ function, parasympathetic stimulation always decreases it, and vice versa; this mutual antagonism is the fundamental organizing principle of the ANS; organs that receive only sympathetic innervation (skin vasculature, adrenal medulla, sweat glands) are not regulated by the parasympathetic division because parasympathetic innervation of these structures is anatomically absent.
• B) The two divisions produce identical effects in the kidney -- both sympathetic (via beta-1 activation of JG cells) and parasympathetic (via M1 activation of JG cells) stimulation increase renin release from the juxtaglomerular apparatus; this convergence on renin release explains why neither ACE inhibitors nor beta-blockers alone can fully suppress the renin-angiotensin system, since blocking one division leaves the other capable of driving renin secretion.
• C) The two divisions are purely antagonistic and never cooperative -- the concept of autonomic cooperation is a didactic simplification that has no physiological basis; any observation suggesting cooperation (such as salivation from both divisions) can be resolved by recognizing that the two glandular cell populations responding are anatomically and functionally separate, and the combined response represents parallel independent activations rather than true cooperation between the two divisions.
• D) Sympathetic and parasympathetic divisions both produce vasoconstriction in the cutaneous vasculature -- sympathetic alpha-1 mediates constriction during cold exposure while parasympathetic M3 mediates constriction during hyperthermia to redirect blood from skin to core; this dual vasoconstrictive effect in skin is unique among effector organs and explains why skin temperature is not a reliable indicator of autonomic state; both ganglionic blockers and selective alpha-1 blockers produce skin warming while selective M3 blockers produce skin cooling.
• E) Sympathetic and parasympathetic divisions are often antagonistic (heart rate, pupil size, bronchial caliber, GI motility), but several important organs receive innervation from only one division, and at some effectors both divisions cooperate toward the same physiological outcome rather than opposing each other; salivary gland secretion is an example of cooperation: both sympathetic (producing thick, viscous saliva rich in mucus and enzymes via alpha-1 and beta-1 activation) and parasympathetic (producing profuse watery saliva via M3 activation) stimulation increase total salivary secretion -- just with different composition; penile erection and ejaculation involve sequential parasympathetic (erection via pelvic nerve NO/VIP-mediated vasodilation) and sympathetic (ejaculation via hypogastric nerve smooth muscle contraction) coordination; the pupil dilator receives only sympathetic innervation (alpha-1) while the sphincter receives only parasympathetic innervation (M3) -- yet both divisions regulate pupil size through their respective muscles rather than opposing actions on the same muscle.

3. Which of the following correctly defines the term sympathomimetic and subcategorizes sympathomimetic agents by their mechanism of action?

• A) Sympathomimetics are drugs that produce effects resembling sympathetic nervous system activation -- they are subcategorized by mechanism: (1) Direct-acting: bind and activate adrenergic receptors directly without requiring NE release (epinephrine, norepinephrine, phenylephrine, isoproterenol, dobutamine, salbutamol, clonidine); (2) Indirect-acting: enter sympathetic nerve terminals via NET and cause NE release from vesicles (tyramine, amphetamine, methamphetamine, ephedrine at some doses) -- their effects are abolished by prior reserpine depletion of NE stores or cocaine/tricyclic NET blockade; (3) Mixed-acting: combine direct receptor activation with indirect NE-releasing properties (ephedrine, pseudoephedrine, metaraminol); (4) Uptake inhibitors: block NET preventing NE reuptake and prolonging endogenous NE action (cocaine, tricyclic antidepressants, atomoxetine) -- these are indirect sympathomimetics that require endogenous NE for activity.
• B) Sympathomimetics are drugs that specifically stimulate alpha-1 adrenergic receptors -- beta-receptor agonists are classified separately as betamimetics and are not considered sympathomimetics; the subcategories of sympathomimetics are: selective alpha-1A (tamsulosin -- prostate), selective alpha-1B (prazosin -- vasculature), and non-selective alpha-1 (phenylephrine -- all alpha-1 subtypes); indirect sympathomimetics do not exist as a pharmacological category since NE release from sympathetic terminals always requires direct receptor activation by an agonist.
• C) Sympathomimetics require an intact sympathetic nervous system to produce their effects -- in patients who have undergone complete sympathectomy or who have autonomic neuropathy with degenerated sympathetic terminals, all sympathomimetics become inactive; this is because all sympathomimetics -- including those claimed to be direct-acting -- actually require interaction with the sympathetic nerve terminal to produce their receptor-activating metabolite; phenylephrine's alpha-1 activation requires prior conversion to norepinephrine by dopamine beta-hydroxylase in the sympathetic terminal before it can activate receptors.
• D) Sympathomimetics are drugs that activate components of the sympathetic nervous system to produce their effects -- they can be divided by specificity: (1) receptor-selective (alpha-1: phenylephrine; alpha-2: clonidine; beta-1: dobutamine; beta-2: salbutamol; beta-3: mirabegron; dopamine D1: fenoldopam); (2) non-selective across receptor subtypes (epinephrine activates alpha-1, alpha-2, beta-1, beta-2, beta-3; norepinephrine activates alpha-1, alpha-2, beta-1 but minimal beta-2; isoproterenol activates beta-1 and beta-2 without alpha activity); and (3) mechanism-selective within the sympathomimetic category (direct vs. indirect vs. mixed vs. uptake-inhibiting).
• E) Sympathomimetics and parasympatholytics produce identical clinical effects -- both drug classes increase heart rate, dilate the pupils, and reduce GI motility; the mechanistic distinction is that sympathomimetics achieve these effects by activating adrenergic receptors while parasympatholytics achieve the same effects by blocking muscarinic receptors; because the end-organ responses are identical, these two drug classes are clinically interchangeable for any indication.

4. Which of the following correctly defines denervation supersensitivity and identifies the mechanism responsible for it at adrenergic synapses?

• A) Denervation supersensitivity is the increased sensitivity of an effector organ to circulating catecholamines following destruction or degeneration of the postganglionic sympathetic nerve supply -- it occurs because the effector cell, deprived of the normal phasic NE input, upregulates postsynaptic adrenergic receptor density (receptor upregulation) and may also enhance receptor-G protein coupling efficiency; additionally, in the absence of the nerve terminal's NET, reuptake of circulating catecholamines at the denervated site is lost, allowing catecholamines to persist longer at postsynaptic receptors; clinically, denervated organs (transplanted hearts, chronically sympathectomized limbs) show exaggerated responses to epinephrine, norepinephrine, and direct-acting sympathomimetics -- but not to indirect sympathomimetics (which require intact nerve terminals for NE release).
• B) Denervation supersensitivity is exclusive to skeletal muscle at the neuromuscular junction -- when a motor neuron is severed, the muscle upregulates acetylcholine receptors throughout the entire muscle surface (not just at the original end plate), producing extreme sensitivity to succinylcholine; this NMJ-restricted phenomenon does not occur at autonomic neuroeffector junctions; administering succinylcholine to a patient with prolonged denervation injury causes massive depolarization-induced potassium efflux, potentially producing fatal hyperkalemia.
• C) Denervation supersensitivity develops at autonomic neuroeffector junctions following postganglionic nerve degeneration through receptor upregulation (increased postsynaptic adrenergic receptor number and/or coupling efficiency) and loss of NET-mediated reuptake (allowing circulating catecholamines to accumulate longer at postsynaptic receptors); the net result is exaggerated responses to direct-acting adrenergic agonists (phenylephrine, norepinephrine, epinephrine) but not to indirect-acting agents (tyramine, amphetamine) which require intact nerve terminals; this distinction is exploited diagnostically -- instillation of hydroxyamphetamine eye drops fails to dilate a pupil with third-order Horner syndrome (postganglionic denervation) while phenylephrine produces exaggerated dilation (supersensitivity), helping to localize the lesion.
• D) Denervation supersensitivity refers to the increased firing rate of postganglionic sympathetic neurons after removal of preganglionic input -- when the preganglionic neuron is cut, the postganglionic neuron loses its tonic inhibitory input (since preganglionic neurons normally inhibit postganglionic firing between action potentials through IPSPs); this disinhibition causes the postganglionic neuron to fire autonomously at a high rate, producing sympathetic hyperactivity at all effectors innervated by the intact postganglionic neurons; this mechanism is exploited therapeutically in stellate ganglion block for hyperhidrosis.
• E) Denervation supersensitivity is a transient phenomenon lasting only 24-48 hours after nerve injury -- the effector cell briefly upregulates receptors in response to loss of NE input, but rapidly downregulates them again as circulating catecholamines occupy the upregulated receptors; the clinical window for exploiting denervation supersensitivity diagnostically (as in pupillary pharmacological testing for Horner syndrome) is therefore limited to the first 48 hours after nerve injury, after which the diagnostic test is no longer interpretable.

5. The Bezold-Jarisch reflex is a cardio-inhibitory reflex originating from ventricular sensory receptors. Which of the following correctly identifies the afferent limb, central processing, and efferent limb of this reflex, and names the clinical situations in which it is pharmacologically relevant?

• A) The Bezold-Jarisch reflex is the same reflex as the baroreceptor reflex -- both originate from the same carotid sinus receptors; the only distinction is that the Bezold-Jarisch reflex describes the acute phase (within 1 second of pressure change) while the baroreceptor reflex describes the chronic adaptation (occurring over minutes to hours); pharmacologically, both reflexes are blocked by the same ganglionic blockers (hexamethonium, trimethaphan) since they share the same ganglionic relay station.
• B) The Bezold-Jarisch reflex is activated exclusively during myocardial infarction -- it cannot be triggered pharmacologically or by any other clinical situation; the reflex is mediated by thromboxane A2 receptors on ventricular myocytes that become exposed to circulating thromboxane during coronary thrombosis; the afferent signal travels via the sympathetic chain (not vagal) to the thoracic spinal cord; the central integration occurs in the intermediolateral cell column at T1-T5; the efferent response is paradoxically sympathetic activation producing tachycardia and hypertension in the non-ischemic zones (explaining why inferior MI sometimes produces reflex hypertension in the anterior wall).
• C) The Bezold-Jarisch reflex produces tachycardia and hypertension (a sympathoexcitatory reflex) rather than bradycardia -- the ventricular C-fiber afferents, when activated, inhibit vagal tone via NTS projections to the nucleus ambiguus (reducing vagal brake on the SA node) while simultaneously activating the RVLM sympathetic center; the net effect is increased heart rate and blood pressure; this reflex is activated by volume overload in congestive heart failure, explaining the compensatory tachycardia that accompanies heart failure despite elevated ventricular filling pressures.
• D) The Bezold-Jarisch reflex (cardiopulmonary reflex, von Bezold-Jarisch reflex): afferent limb -- unmyelinated C-fiber mechanoreceptors and chemoreceptors in the inferoposterior left ventricular wall and coronary sinus detect ventricular stretch, chemical stimuli (serotonin, bradykinin, veratridine, capsaicin), or ischemic metabolites; afferents travel via vagal afferents (CN X) to the NTS; central processing -- NTS activates the dorsal motor nucleus of the vagus and nucleus ambiguus, increasing efferent vagal outflow; efferent limb -- increased vagal M2 activation produces bradycardia, hypotension, and vasodilation (the triad); clinical pharmacological relevance: (1) inferior STEMI with RCA occlusion (LV inferior wall ischemia activating BJR afferents -- producing sinus bradycardia and hypotension; treated with atropine to block vagal bradycardia); (2) intrathecal opioids activating ventricular C-fibers -- explaining the bradycardia sometimes seen with intrathecal morphine; (3) serotonin receptor agonists and antagonists (5-HT3 receptors are expressed on cardiac C-fiber afferents -- granisetron and ondansetron occasionally produce bradycardia via this pathway).
• E) The Bezold-Jarisch reflex is triggered by high-pressure baroreceptors in the aortic arch detecting extreme hypertension (systolic above 200 mmHg) -- it is an emergency override reflex that produces severe bradycardia to protect against hypertensive intracranial hemorrhage; the afferent limb travels via the aortic nerve (branch of CN X) and the reflex is clinically relevant during hypertensive crises, explaining why extremely high blood pressure is sometimes accompanied by paradoxical bradycardia; phentolamine (alpha-blocker) activates this reflex while phenylephrine suppresses it.

6. Which of the following correctly defines the term pharmacological antagonism and distinguishes competitive reversible antagonism from irreversible (non-competitive) antagonism in the context of adrenergic pharmacology?

• A) Pharmacological antagonism occurs when two agonists compete at the same receptor -- it describes only agonist-agonist competition; antagonists by definition cannot produce pharmacological antagonism because they have zero intrinsic activity and produce no biological response; the correct term for an antagonist reducing an agonist's effect is pharmacological inhibition, not antagonism.
• B) Competitive reversible antagonism: the antagonist competes with the agonist for the same binding site on the receptor; occupancy is determined by the relative concentrations and affinities of antagonist versus agonist; increasing agonist concentration can overcome the block (surmountable antagonism); the effect is a parallel rightward shift of the agonist concentration-response curve with preserved maximal response (Emax) -- the Emax is unchanged because at sufficiently high agonist concentrations the antagonist is displaced; atropine, propranolol, prazosin, and phentolamine are reversible competitive antagonists; irreversible (non-competitive) antagonism: the antagonist binds covalently or with extremely high affinity to the receptor, forming a stable complex that cannot be overcome by increasing agonist concentration; the effect is a reduction in Emax (non-surmountable) regardless of agonist concentration because the total number of available receptors is permanently reduced; phenoxybenzamine (irreversible alpha-1 and alpha-2 blocker) is the prototype in adrenergic pharmacology; its irreversible binding is the rationale for its use in pheochromocytoma preoperative preparation.
• C) Competitive antagonism shifts the agonist dose-response curve downward (reducing Emax) while preserving the EC50 -- this is because competitive antagonists reduce the number of functional receptors available while leaving the receptor-G protein coupling efficiency unchanged; irreversible antagonism shifts the curve rightward (increasing EC50) while preserving Emax -- because irreversible antagonists trap receptors in the inactive R conformation without reducing receptor number, simply requiring higher agonist concentrations to activate the remaining receptors.
• D) Chemical antagonism and pharmacological receptor antagonism are synonymous terms -- both describe drug interactions that reduce the effect of an agonist regardless of whether the interaction occurs at the receptor level, in the bloodstream, or at a secondary pathway; protamine sulfate reversing heparin, pralidoxime reactivating AChE, and propranolol blocking beta-1 receptors are all equivalent examples of pharmacological antagonism; the distinction between competitive and non-competitive is clinically irrelevant since the endpoint (reduced agonist effect) is identical.
• E) The Schild equation applies only to irreversible antagonism -- it describes the permanent relationship between antagonist concentration and receptor inactivation over time; competitive reversible antagonism cannot be described by the Schild equation because the reversible binding creates a dynamic equilibrium that the equation cannot model; the pA2 value (negative log of the antagonist concentration producing a 2-fold rightward shift) is therefore a property of irreversible antagonists only and cannot be measured for reversible drugs like atropine or propranolol.

7. The autonomic nervous system undergoes predictable changes with aging that alter the pharmacological responses of elderly patients to autonomic drugs. Which of the following most accurately characterizes these age-related changes and their clinical pharmacological consequences?

• A) Aging produces uniform upregulation of both sympathetic and parasympathetic receptor subtypes throughout the body -- elderly patients show enhanced responses to all autonomic drugs, requiring lower doses for equivalent effects; this pharmacodynamic sensitivity is uniform across receptor types; the only exception is the SA node, which shows reduced automaticity with aging requiring higher atropine doses to increase heart rate.
• B) Aging selectively impairs parasympathetic function while preserving sympathetic function completely -- elderly patients have reduced resting vagal tone (explaining their higher resting heart rates compared to young adults), reduced vagally mediated cardiac deceleration in response to carotid sinus massage, and reduced salivary and lacrimal output; sympathetic function (vasoconstriction, pupillary dilation, sweating) is fully preserved and actually enhanced due to upregulation of alpha-1 receptors compensating for the lost vagal tone.
• C) Age-related autonomic changes are clinically significant and bidirectional: (1) Reduced beta-adrenergic responsiveness: aging decreases beta-1 and beta-2 receptor coupling efficiency (not necessarily receptor density) -- the chronotropic response to isoproterenol, the inotropic response to dobutamine, and the bronchodilatory response to salbutamol are all attenuated; this reflects reduced Gs-adenylyl cyclase coupling efficiency and reduced downstream cAMP responsiveness; (2) Reduced baroreflex sensitivity: aging impairs the arterial baroreceptor reflex arc (reduced baroreceptor mechanosensitivity, impaired NTS processing, and attenuated efferent responses) -- elderly patients show less compensatory heart rate increase in response to orthostatic stress, predisposing to orthostatic hypotension; (3) Enhanced sensitivity to anticholinergic drugs: aging reduces the cholinergic reserve of the CNS (basal forebrain cholinergic neuron loss) and reduces the safety margin for CNS muscarinic blockade -- elderly patients develop anticholinergic delirium at doses that are well-tolerated by young adults; (4) Reduced renal drug clearance and altered drug distribution: pharmacokinetic changes amplify all pharmacodynamic effects.
• D) The most clinically important age-related autonomic change for drug prescribing is the progressive reduction in beta-adrenergic receptor responsiveness with aging -- this means that elderly patients require higher doses of beta-blockers to achieve the same degree of beta-blockade as younger patients; the dose of metoprolol needed for target heart rate control in elderly patients with AF is approximately 3-fold higher than in young adults; this age-related pharmacodynamic tolerance to beta-blockade is additive with the pharmacokinetic changes of aging (reduced hepatic first-pass, reduced renal clearance) which would otherwise increase drug exposure.
• E) Age-related autonomic changes include: reduced beta-adrenergic responsiveness (impaired Gs coupling, reduced chronotropic and inotropic response to catecholamines and beta-agonists), impaired baroreflex sensitivity (orthostatic hypotension risk), enhanced CNS anticholinergic sensitivity (delirium risk), and increased sensitivity to alpha-1 antagonists (orthostatic hypotension from reduced compensatory vasoconstriction); together these changes define a set of pharmacological vulnerabilities that make elderly patients particularly prone to adverse drug reactions from autonomic drugs; the prescribing principle is to start low, go slow, and monitor for orthostatic hypotension and anticholinergic delirium as priority endpoints.

8. Which of the following correctly identifies the concept of physiological antagonism and provides an example from autonomic pharmacology that distinguishes it from pharmacological (receptor-level) antagonism?

• A) Physiological antagonism occurs when two drugs act at the same receptor, with one producing agonism and the other producing competitive blockade -- epinephrine and propranolol are physiological antagonists because epinephrine activates beta-1 receptors and propranolol blocks them at the same binding site; this receptor-level competition is distinguished from pharmacological antagonism, which describes drugs acting at entirely separate receptor systems to produce opposing physiological outcomes without competing for the same binding site.
• B) Physiological antagonism describes drug interactions that cancel each other's effects in the bloodstream rather than at receptors or effectors -- protamine sulfate neutralizing heparin by ionic interaction is the prototype of physiological antagonism; chelation of digoxin by cholestyramine is another example; the term physiological in this context refers to the normal body fluid compartment where the interaction takes place rather than the pharmacological receptor environment.
• C) Physiological antagonism and pharmacological antagonism are identical concepts applied at different levels of biological organization -- pharmacological antagonism describes receptor-level competition while physiological antagonism describes the same competition at the organ level; any receptor antagonist (propranolol blocking beta-1) can be reclassified as a physiological antagonist when viewed from the perspective of the organ (heart rate reduction).
• D) Physiological antagonism describes the situation where two drugs produce opposing effects through entirely different receptors or mechanisms, rather than competing at the same binding site -- neither drug interferes with the other's receptor binding; the opposing physiological responses cancel each other at the level of the effector organ; examples in autonomic pharmacology: epinephrine (beta-2 agonist producing bronchodilation via Gs-cAMP-MLCK inhibition) and methacholine (M3 agonist producing bronchoconstriction via Gq-IP3-calcium-MLCK activation) are physiological antagonists in the bronchial smooth muscle -- each acts at its own receptor via its own second messenger but produces opposite effects on airway caliber; the methacholine bronchoprovocation test exploits the balance between endogenous sympathetic bronchodilatory tone and exogenous cholinergic bronchoconstriction; epinephrine cannot reverse anaphylaxis by competing with histamine at H1 receptors (different receptors entirely) but by physiologically antagonizing the vasodilation and bronchoconstriction through its own alpha-1 and beta-2 receptor activation.
• E) Physiological antagonism requires the two drugs to act on the same physiological parameter through the same effector cell -- if the two drugs affect different effector cells even within the same organ, the interaction is classified as tissue-specific antagonism rather than physiological antagonism; epinephrine and histamine are therefore not physiological antagonists because epinephrine acts on mast cells while histamine acts on smooth muscle receptors, making them tissue-specific antagonists rather than true physiological antagonists.